The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Home | Hakkımızda | Komiteler

Komiteler

5 ERA Komitelerini Keşfedin

ERA Komiteleri İçin Genel Kurallar